BioWorld Asia

Sep. 22, 2004

BMS Drops Flamel’s Basulin; Shares Suffer 22 Percent Hit

It may be true that “two out of three ain’t bad” - but two pieces of good news and one seriously negative item added up to trouble on Wall Street for Flamel Technologies SA. (BioWorld International) Read More

Acambis Falls On Cancelled Smallpox Contract From CDC

Angiogenesis Study Turns Up Male Infertility Surprise Factor

CeNeS Reports Positive Phase III M6G Data In Post-Operative Pain

Active Biotech Seeking SEK150M In Convertible Debentures Issue

Genetic Markers Of Epidermis Cell Differentiation Identified

Novagali Pharma Completes Second Round For EUR14.2M

EU Medicines Guidelines Up For General Comment

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...